Filing Analysis
Crescent Biopharma, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of earnings via a press release.
📋 Key Facts
- The company issued a press release on July 30, 2026, regarding financial results for the quarter ended June 30, 2026.
- The report was signed by CEO Joshua Brumm.
Crescent Biopharma, Inc. has entered into an underwriting agreement to conduct a public offering of 8,094,793 ordinary shares and 525,897 pre-funded warrants at $14.50 per share. The company expects to raise approximately $115.9 million in net proceeds to extend its cash runway into the second half of 2028.
🚩 Red Flags
- Dilution risk due to significant issuance of new ordinary shares and pre-funded warrants.
- Pre-funded warrants allow large investors to bypass beneficial ownership limits (up to 19.99%), potentially concentrating ownership.
📋 Key Facts
- Public offering of 8,094,793 ordinary shares at $14.50 per share.
- Issuance of 525,897 pre-funded warrants at $14.499 per warrant.
- Underwriters: Jefferies LLC and TD Securities (USA) LLC.
- Expected net proceeds: ~$115.9 million (up to ~$133.5 million if over-allotment is exercised).
- Estimated cash runway extension: Into the second half of 2028.
- Underwriters have a 30-day option to purchase up to 1,293,103 additional shares.
Crescent Biopharma, Inc. provided preliminary unaudited cash and cash equivalents information for the quarter ended June 30, 2026. The company reports an estimated cash position of approximately $171.6 million.
📋 Key Facts
- As of June 30, 2026, estimated cash and cash equivalents: ~$171.6 million.
- Financial data is preliminary, unaudited, and based on management estimates.
- The information is subject to completion of financial closing procedures.
Crescent Biopharma entered into a major strategic transaction with Sichuan Kelun-Biotech involving two significant license agreements for CR-001 and SKB105. Simultaneously, the company announced a $185 million private placement to bolster its cash runway through 2028.
🚩 Red Flags
- Significant contingent liabilities: Potential for over $1.3 billion in total milestone payments under the SKB105 agreement.
- Complex licensing structure involving multiple parties (Kelun-Biotech, Paragon Therapeutics) and territorial splits.
📋 Key Facts
- Entered into 'CR-001 License Agreement' with Kelun-Biotech: Crescent grants exclusive rights in Greater China; receives $20M upfront, up to $30M in development milestones, and tiered royalties.
- Entered into 'SKB105 License Agreement': Crescent licenses SKB105 from Kelun-Biotech for all territories outside Greater China; agrees to pay $80M upfront, up to $345M in development milestones, and up to $902.5M in sales-based milestones.
- Announced a private placement of 13,795,685 ordinary shares/pre-funded warrants at $13.41 per share for an aggregate of ~$185 million.
- The company expects the proceeds from the private placement to fund operations into 2028.
- Amendment No. 1 made to Paragon Therapeutics, Inc. license regarding CR-001 to align with the Kelun-Biotech deal.
Crescent Biopharma, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025 via a press release.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results are provided in Exhibit 99.1 as a press release.
- Report date: November 6, 2025.
Crescent Biopharma announced the adoption of a new Executive Severance Plan for Vice President-level employees and above, alongside the release of Q2 2025 financial results. The filing details specific severance multipliers and accelerated vesting terms triggered by qualifying terminations or changes in control.
🚩 Red Flags
- Establishment of significant severance liabilities/potential 'parachute payments' for executives.
📋 Key Facts
- Board approved an Executive Severance Plan on July 29, 2025.
- Plan covers employees with the title of Vice President or higher.
- CEO (Joshua Brumm) receives a 1.0x salary multiplier and 12 months of COBRA coverage for qualifying terminations; enhanced to 1.5x/18 months in a Change in Control.
- Other executive officers receive 1.0x salary multiplier and 12 months of COBRA (enhanced to 1.25x/15 months in a CIC).
- Ryan Lynch is excluded from the standard multipliers, receiving lower 0.75x/9-month terms.
- The plan includes provisions for accelerated vesting of equity awards upon qualifying terminations after March 17, 2026.
- Company issued Q2 2025 financial results on July 31, 2025.
GlycoMimetics, Inc. has completed a business combination with Crescent Biopharma, Inc., resulting in a name change to Crescent Biopharma, Inc. The transaction included a significant $200 million pre-closing financing and a reverse stock split.
🚩 Red Flags
- Reverse stock split occurred immediately prior to the merger closing.
- Extreme dilution: Original GlycoMimetics shareholders now own only ~2.7% of the combined entity.
- Significant issuance of pre-funded warrants with a $0.001 exercise price, which may lead to further dilution.
📋 Key Facts
- Transaction closed on June 13, 2025.
- Crescent Biopharma, Inc. is the surviving entity; GlycoMimetics changed its name to Crescent Biopharma, Inc.
- Exchange Ratio: 0.1445 shares of Company common stock for each share of Crescent common stock (adjusted for reverse split).
- Post-merger ownership: Crescent securityholders own ~97.3% of the Company; GlycoMimetics securityholders own ~2.7%.
- Crescent Pre-Closing Financing raised approximately $200 million via issuance of 85,506,824 shares and 19,149,690 pre-funded warrants.
- Lock-up agreements implemented for certain executives/directors for 180 days post-effective time.
GlycoMimetics, Inc. stockholders approved a comprehensive merger with Crescent Biopharma, Inc., which includes a significant 1-for-100 reverse stock split and redomestication to the Cayman Islands. The combined entity will trade as 'Crescent Biopharma, Inc.' under ticker CBIO starting June 16, 2025.
🚩 Red Flags
- Reverse stock split (1-for-100) is highly dilutive to share count and often a sign of extreme low share price management.
- Redomestication to the Cayman Islands can sometimes be used to reduce regulatory oversight or facilitate specific tax/corporate structures, though common in biotech mergers.
- Significant change in capital structure and corporate identity.
📋 Key Facts
- Stockholders approved a merger with Crescent Biopharma, Inc., resulting in a new corporate structure where the combined company trades as Crescent Biopharma, Inc. (f/k/a GlycoMimetics, Inc.).
- A 1-for-100 reverse stock split was approved and finalized by the Board of Directors.
- The reverse split is expected to reduce outstanding common stock from ~64.5 million shares to approximately 0.6 million shares.
- Authorized shares will increase from 150,000,000 to 175,000,000.
- The company will redomesticate from Delaware to the Cayman Islands.
- Post-merger, total issued and outstanding common stock is expected to be ~14.8 million shares (25.3 million on a fully-diluted basis).
- New ticker symbol: CBIO; New CUSIP: 38000Q201.
GlycoMimetics is providing supplemental disclosures regarding its pending reverse merger with Crescent Biopharma. The filing highlights significant financial distress, including the inability to prepare meaningful financial projections due to going-concern uncertainties and a highly discounted $8 million enterprise valuation for GlycoMimetics.
🚩 Red Flags
- Going concern uncertainties mentioned as a reason why financial projections could not be prepared.
- Extremely low enterprise valuation ($8M) relative to the scale of the concurrent PIPE ($125M).
- Complete replacement of management (no GlycoMimetics executives to be retained post-merger).
- History of asset liquidation (rivipansel program sold for $1M) to manage cash.
📋 Key Facts
- The company is undergoing a reverse merger with Crescent Biopharma, Inc.
- GlycoMimetics' enterprise value was ascribed at $8,000,000 in the proposed transaction.
- Crescent Biopharma is targeting a concurrent $125,000,000 PIPE financing.
- The merger will result in GlycoMimetics changing its name to 'Crescent Biopharma, Inc.'
- Crescent has stated it does not plan to retain or employ any GlycoMimetics executives post-merger.
- GlycoMimetics sold its rivipansel program to Biossil Inc. for approximately $1 million in cash on September 5, 2024.
GlycoMimetics, Inc. has entered into an amendment to its merger agreement with Crescent Biopharma, Inc., clarifying RSU treatment and voting mechanics for preferred stock. The transaction is structured such that former Crescent shareholders will own approximately 97.4% of the combined company, effectively resulting in a reverse takeover of GlycoMimetics.
🚩 Red Flags
- Extreme dilution of existing GlycoMimetics shareholders (existing holders to own only ~2.6% post-merger).
- The transaction structure indicates a reverse takeover by Crescent Biopharma.
- Low projected net cash position ($1.8 million) at the time of closing.
📋 Key Facts
- Amendment to Merger Agreement dated April 28, 2025.
- Crescent common stock is estimated to receive ~15.4192 shares of GlycoMimetics common stock per share.
- Post-merger ownership: Crescent shareholders expected to own ~97.4% of the combined company; GlycoMimetics securityholders expected to own ~2.6%.
- The transaction assumes GlycoMimetics' net cash at closing will be $1.8 million.
- Amendment addresses RSU assumption and voting mechanics for Series A Non-Voting Convertible Preferred Stock.
GlycoMimetics, Inc. announced a major leadership overhaul including the resignation of its entire Board of Directors and the departure of both the CEO and CFO. Additionally, the company reported the termination of a material collaboration agreement with Apollomics (Hong Kong) Limited.
🚩 Red Flags
- Mass exodus of leadership: Simultaneous resignation of the entire Board and both top executives (CEO/CFO).
- Loss of material revenue/partnership stream via termination of the Apollomics agreement.
- Significant cash outflows for executive severance totaling nearly $1.85M plus COBRA premiums.
- High-risk period: The company is undergoing a major transaction (Crescent Biopharma) while simultaneously losing all core leadership.
📋 Key Facts
- CEO Harout Semerjian resigned effective February 21, 2025; receiving $1,365,456 severance and a 12-month consulting agreement at $700/hour.
- CFO Brian Hahn resigned effective February 21, 2025; receiving $480,991 severance and a consulting agreement through Sept 30, 2025 or until change in control.
- Four Board members (Mark Goldberg, Scott Jackson, Rachel King, and Scott Koenig) resigned effective February 21, 2025.
- Apollomics (Hong Kong) Limited terminated its Collaboration and License Agreement for uproleselan and GMI-1687; termination effective in ~90 days.
- The company is involved in a proposed transaction with Crescent Biopharma, Inc. involving an S-4 registration statement.
GlycoMimetics, Inc. has amended its merger agreement with Crescent Biopharma, Inc., significantly restructuring the financing and ownership of the combined entity. The amendment shifts $200 million in financing to occur immediately prior to the closing of the merger into Crescent, effectively resulting in a reverse takeover scenario.
🚩 Red Flags
- Significant dilution of existing GlycoMimetics shareholders (down to 3.10% ownership).
- Transaction structure functions as a reverse takeover by Crescent Biopharma.
- High concentration of equity in former Crescent holders and new investors.
📋 Key Facts
- Amendment to Merger Agreement dated February 14, 2025.
- The transaction will result in GlycoMimetics securityholders owning approximately 3.10% of the combined company.
- Former holders of Crescent securities are expected to own approximately 96.90% of the combined company on a fully-diluted basis.
- Crescent shareholders are estimated to receive approximately 14.9149 shares of GlycoMimetics for each share of Crescent capital stock.
- $200.0 million in securities will be purchased by investors into Crescent immediately prior to the merger closing, rather than into GlycoMimetics post-merger.
- The combined company's net cash at closing is expected to be $1.8 million.
GlycoMimetics, Inc. announced the planned departures of its CEO, Harout Semerjian, and CFO, Brian Hahn, effective no later than March 31, 2025. Both executives will transition to consulting roles to assist through the expected closing of a proposed merger with Crescent Biopharma, Inc.
🚩 Red Flags
- Simultaneous departure of both CEO and CFO creates significant leadership instability during a critical merger period.
- Management turnover occurring right before a major corporate transaction (merger) can signal internal friction or uncertainty regarding deal terms/future direction.
📋 Key Facts
- CEO Harout Semerjian notified the board of intent to cease employment by March 31, 2025.
- CFO Brian Hahn notified the board of intent to cease employment by March 31, 2025.
- Both executives will enter into consulting agreements to provide services on an as-needed basis.
- The transition is timed to coincide with the expected closing of a proposed merger with Crescent Biopharma, Inc.
GlycoMimetics, Inc. has updated its investor presentation in connection with a proposed merger with Crescent Biopharma, Inc. The filing serves to provide updated information to shareholders regarding the transaction under Regulation FD.
🚩 Red Flags
- The filing notes that information regarding directors' and officers' interests in the proposed transaction will be disclosed in future proxy statements, which is standard but requires scrutiny for potential conflicts/related-party issues once released.
📋 Key Facts
- The filing relates to an updated investor presentation dated January 2025.
- The update is being made in connection with a proposed merger between GlycoMimetics, Inc. and Crescent Biopharma, Inc.
- GlycoMimetics intends to file a proxy statement regarding the transaction.
- Directors and executive officers of both companies may be considered participants in the solicitation of proxies.
GlycoMimetics, Inc. received a notice from Nasdaq granting an 180-day extension to regain compliance with the minimum bid price requirement. The company's stock has been transferred from the Nasdaq Global Market to the Nasdaq Capital Market.
🚩 Red Flags
- Delisting notice/non-compliance with Nasdaq minimum bid price rule.
- Potential for an upcoming reverse stock split to regain compliance.
- Downgrade in market tier (Nasdaq Global Market to Nasdaq Capital Market).
📋 Key Facts
- Nasdaq granted an extension until June 16, 2025, to meet the minimum closing bid price requirement under Rule 5550(a)(2).
- The company's common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective December 20, 2024.
- To regain compliance, the stock must maintain a $1.00 minimum bid price for at least 10 consecutive business days.
- The company explicitly mentioned that a reverse stock split is one of the options being considered to resolve the deficiency.
GlycoMimetics, Inc. updated its investor presentation regarding a proposed merger with Crescent Biopharma, Inc. The filing serves to provide updated information to shareholders in connection with the ongoing solicitation of proxies for the transaction.
🚩 Red Flags
- The filing notes that additional information regarding directors' interests in the transaction will be disclosed in future proxy statements, which is standard but requires scrutiny for potential conflicts or dilution.
📋 Key Facts
- The company and Crescent Biopharma, Inc. updated their joint investor presentation on November 7, 2024.
- The update is related to a proposed merger between GlycoMimetics and Crescent.
- GlycoMimetics intends to file a proxy statement with the SEC regarding the transaction.
- Directors and executive officers of both companies may be considered participants in the solicitation of proxies.
GlycoMimetics, Inc. has entered into a definitive merger agreement with Crescent Biopharma, Inc., which will result in the combined company being controlled by Crescent stockholders (86.21% ownership). The transaction includes significant restructuring, including a planned reverse stock split and redomiciliation to the Cayman Islands or Bermuda.
🚩 Red Flags
- Significant dilution for existing GlycoMimetics stockholders (retaining only ~13.8% ownership).
- Planned reverse stock split, often used to maintain Nasdaq listing compliance.
- Redomiciliation from Delaware to a non-US jurisdiction (Cayman Islands or Bermuda) can impact investor protections and tax treatment.
- Transaction is highly contingent on securing $100M in new financing.
📋 Key Facts
- Merger Agreement entered into on October 28, 2024.
- Crescent stockholders will own approximately 86.21% of the combined company post-merger.
- GlycoMimetics stockholders will own approximately 13.79% of the combined company post-merger.
- The transaction is contingent upon GlycoMimetics securing at least $100,000,000 in financing.
- Proposed changes include a reverse stock split and redomiciliation to the Cayman Islands or Bermuda.
- Expected closing date: Second quarter of 2025.
GlycoMimetics is undergoing a massive corporate restructuring, including an 80% reduction in headcount and a strategic review of its business operations. This follows FDA feedback indicating that their lead candidate, uproleselan, requires additional clinical trials.
🚩 Red Flags
- Massive workforce reduction (80% of headcount) indicates severe distress or pivot in business model.
- Regulatory setback: FDA feedback requires an additional clinical trial for lead product uproleselan, increasing capital requirements and time to market.
- Strategic review/exploration of alternatives often precedes bankruptcy, sale, or liquidation.
- Departure of key executive (Chief Medical Officer) during a restructuring phase.
📋 Key Facts
- Reduction in workforce by 26 employees, representing approximately 80% of total headcount.
- The reduction is expected to be substantially complete by July 31, 2024.
- Anticipated one-time charges of approximately $3.6 million related to severance and benefits.
- Chief Medical Officer Dr. Edwin Rock will depart on July 31, 2024, but will serve as a consultant through January 31, 2025.
- The company is exploring strategic alternatives to maximize shareholder value.
GlycoMimetics, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement after its stock traded below $1.00 for 30 consecutive business days. The company has until December 18, 2024, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice (Nasdaq non-compliance)
- Stock price has been below $1.00 for 30 consecutive business days
- Risk of delisting from the Nasdaq Global Market
📋 Key Facts
- Received Nasdaq notice on June 21, 2024.
- Non-compliance with Nasdaq Listing Rule 5450(a)(1) due to minimum bid price deficiency.
- The company has a 180-calendar day grace period to regain compliance (until December 18, 2024).
- To cure the deficiency, stock must meet or exceed $1.00 for at least 10 consecutive business days.
- Potential to transfer to Nasdaq Capital Market for an additional 180-day period if requirements are met.
GlycoMimetics, Inc. announced the granting of performance-based stock options to its named executive officers (NEOs). The vesting of these awards is tied directly to FDA approval of the company's product candidate, uproleselan.
🚩 Red Flags
- Significant discrepancy between the strike price of recent service-based options ($3.11) and these new performance-based options ($0.2589), indicating a substantial drop in stock value since January 2024.
📋 Key Facts
- Performance-based stock options granted on June 10, 2024.
- Exercise price for new awards: $0.2589 per share.
- Vesting condition: Full vesting upon FDA approval of uproleselan for acute myeloid leukemia treatment.
- CEO Harout Semerjian awarded 521,250 shares; CFO Brian Hahn and CMO Edwin Rock, M.D. each awarded 187,500 shares.
- The new awards are in addition to service-based options granted on January 12, 2024, which have an exercise price of $3.11 per share.
GlycoMimetics, Inc. issued a press release regarding comprehensive results from its pivotal Phase 3 clinical trial of uproleselan for patients with relapsed/refractory acute myeloid leukemia (AML). The company also hosted a webcast to discuss these findings.
🚩 Red Flags
- Clinical trial results for pivotal studies in micro-cap biotech often lead to high volatility or binary outcomes; the specific direction of efficacy vs. safety was not detailed in the 8-K text itself.
📋 Key Facts
- Announced comprehensive results from the pivotal Phase 3 study of uproleselan in R/R AML on June 4, 2024.
- Conducted a live webcast to discuss clinical trial data and corporate strategy.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure) and is considered 'furnished' rather than 'filed'.
GlycoMimetics, Inc. announced its Q1 2024 financial results and released topline data from its pivotal Phase 3 clinical trial of uproleselan for relapsed/refractory acute myeloid leukemia (AML). The filing also includes an updated corporate presentation.
🚩 Red Flags
- Clinical trial data is 'pivotal'; failure to meet primary endpoints in Phase 3 can be catastrophic for micro-cap biotech firms, though specific results were not detailed in the text of the 8-K itself (referencing Exhibit 99.1).
📋 Key Facts
- Reported financial results for the first quarter ended March 31, 2024.
- Released topline results from a pivotal Phase 3 clinical trial of uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML).
- Issued an updated corporate presentation for investor meetings.
GlycoMimetics, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on May 1, 2024. Key outcomes included the election of directors, ratification of Ernst & Young LLP as auditors, and approval to increase authorized common stock from 100 million to 150 million shares.
🚩 Red Flags
- Increase in authorized shares (from 100M to 150M) can lead to future dilution if used for equity financing, though this is standard for micro-cap biotech companies needing capital.
📋 Key Facts
- Annual Meeting held on May 1, 2024, with 78.3% (50,481,107 shares) of outstanding shares represented.
- Stockholders approved an amendment to increase authorized common stock from 100,000,000 to 150,000,000 shares.
- Ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for FY2024.
- Approved an amendment to include officer exculpation provisions per Delaware law.
- Elected Daniel Junius and Rachel King to the Board of Directors.
GlycoMimetics, Inc. issued an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023.
📋 Key Facts
- Report date: March 27, 2024
- Reporting period: Fourth quarter and full year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing financial highlights.
- Information is furnished under General Instruction B.2 of Form 8-K and not 'filed' for liability purposes.
GlycoMimetics, Inc. filed an 8-K to provide a corporate presentation intended for use in anticipated investor meetings under Regulation FD.
📋 Key Facts
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- A corporate presentation dated March 1, 2024, was attached as Exhibit 99.1.
- The information provided in the exhibit is furnished but not 'filed' for purposes of Section 18 liability.
GlycoMimetics entered into a Project Agreement with Patheon Manufacturing Services (a Thermo Fisher Scientific company) to manufacture and supply its drug candidate, uproleselan, for commercial sale upon FDA approval. The agreement covers manufacturing, raw materials, packaging, and quality control services.
📋 Key Facts
- Agreement signed on January 2, 2024, with Patheon Manufacturing Services LLC (Thermo Fisher Scientific).
- Purpose: Commercial manufacture and supply of uproleselan upon FDA marketing approval.
- Scope includes manufacturing injectable supplies from Company-supplied API, plus raw materials, packaging, and quality control testing.
- Initial term runs through December 31, 2026, with automatic three-year renewals.
- The Company has provided volume forecasts through the year 2027.